Search
forLearn
5 / 801 resultslearn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
learn Thymosin Beta 4
learn pyrrolidone carboxylic acid
learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
Research
5 / 1000+ resultsresearch Development of polymeric nanoparticles with controlled drug release for dermal application
Polymeric nanoparticles effectively control corticosteroid release and penetration for skin applications.
research Swellable Microneedles in Drug Delivery and Diagnostics
Swellable microneedles could improve drug delivery and diagnostics but need more research on materials and technology integration.
research Preparation, Optimization, In vitro Evaluation and Ex vivo Permeation Studies of Finasteride loaded gel Formulations Prepared by using Response SurfaceMethodology
The combination of propylene glycol and Tween® 80 improves finasteride gel effectiveness.
research Dissolving microneedle array patches containing mesoporous silica nanoparticles of different pore sizes as a tunable sustained release platform
Microneedle patches with different pore sizes can effectively deliver drugs and trigger strong immune responses.
research Bioengineered microneedles and nanomedicine as therapeutic platform for tissue regeneration
Bioengineered microneedles and nanomedicine offer promising, precise treatments for tissue regeneration.
Community Join
5 / 1000+ resultscommunity Follicum releases some data from previous phase 2a trial
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
community Coegin Pharma to release Follicopeptide (FOL005) by Q2 2025
Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.
community PP405 Phase 2a press release with early results
PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.
community PP405: The Ultimate Hair Loss Drug for Complete Hair Growth
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
community Dr. Gary Linkov has just released a video talking about PP405.
PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.